drugset / Trial / NCT01979614

Study of the Vascular Effects of Serelaxin

NCT01979614

Phase 2 Completed 58 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.

Timeline

Start
2014-02-03
Primary completion
2016-08-17
Completion
2016-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Serelaxin Protein / enzyme biologic 30 ug/kg Intravenous